Driving innovation through strong alliances

 

At Novo Nordisk, we are interested in innovative compounds and technologies that address unmet medical needs and have the potential to improve the lives of people with serious chronic diseases. We are interested in development stages from target identification to clinical stage.

 

Download “Partnering for innovation” brochure 
 


We partner for innovation in…

partnering diabetes

Diabetes

  • Novel modalities that show, for example, insulin sensitisation, glucose regulation with added benefit on weight or comorbidities, improvement of beta-cell health
  • Next generation insulin and GLP-1 receptor agonists with added benefit to glucose control (for example, weight or comorbidities)
  • Novel modalities addressing immunotolerance for type 1 diabetes

Obesity

  • Novel modalities that affect appetite regulation and/or energy expenditure and mechanisms of action that impact breakthrough weight loss (>20%)
  • Novel modalities that prevent loss of lean body mass during rapid weight loss
  • Novel modalities that specifically address obesity-related complications, such as diabetes, cardiovascular disease and/or NASH pathways                                                                                                                                    
partnering obesity
partnering atherosclerosis

Atherosclerosis

  • Novel modalities with potential to address residual risk in patients with high cardiovascular risk on top of cholesterol lowering therapies

NASH

  • Novel modalities that address fibrosis and inflammation
partnering atheros
partnering haemophilia

Haematological and endocrine disorders

  • Novel bypassing agents for prophylaxis in haemophilia
  • Cell and gene-based therapy approaches
  • Clinical assets in haematological and endocrine disorders

Other cardio-metabolic diseases

Heart failure
Chronic kidney disease

Technological focus areas

  • Cell therapies (stem cell) or differentiation protocols for chronic serious diseases
  • Cell encapsulation technologies
  • Novel platforms for oligonucleotide or RNA-based therapies
  • Peptide and protein technology platforms (expression, purification and modification)
  • Formulation and drug delivery technologies with focus on oral delivery
  • Exosomes and other cell-penetrating technologies
partnering tech

Bringing expertise together in tailored partnerships

A partnership with Novo Nordisk is a collaborative partnership, where we work together and combine our capabilities to create new human therapeutics, scientific insights, or enabling technologies. We have used a number of collaboration models in the past, and we are open and flexible to explore new modes of collaboration to build long-term and fruitful alliances based on trust.


Examples of our current partnership models include…

partnering hypo

Public-private partnerships

Novo Nordisk takes part in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.

Research collaborations

Collaborations with external partners are essential to our R&D efforts at Novo Nordisk. We constantly seek new partnerships with leading individual experts and research teams within biotechnology, academia, as well as with other pharmaceutical companies.

partnering kally
partnering licensing

Licensing deals

Novo Nordisk is always interested in gaining access to the latest relevant innovation and research, and we regularly license intellectual property rights to new technologies or assets from leading external partners. License agreements can be structured in many ways, but our objective is always to expand the Novo Nordisk pipeline with new exciting assets and/or to support projects with critical technologies.

Acquisitions

Novo Nordisk will also consider the acquisition of small start-ups or parts of biotech companies in cases where there is a good match in complementary expertise and mutual interest.

partnering ziylo

Contact us

Miriam Frieden

"We have the skills and experience within drug and device development to turn your ideas into treatment solutions for patients."

Miriam Frieden
Vice President, Search & Evaluation 
Novo Nordisk

Contact us

 

 

Where to meet us

Mads Krogsgaard

We attend partnering events all over the world to meet with new potential partners. If you wish to arrange a meeting, please contact us.



Our events calendar